Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

Cancer

Volumn 79, Issue 11, 1997, Pages 2162-2170

  Ross, Jeffrey S ^a   Sheehan, Christine E ^a   Hayner Buchan, Alida M ^a   Ambros, Robert A ^a   Kallakury, Bhaskar V S ^a   Kaufman Jr , Ronald P ^a   Fisher, Hugh A G ^a   Rifkin, Matthew D ^a   Muraca, Patrick J ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b Oncor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; COSMID; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE NEU; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PLOIDIES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2;

EID: 0030978334     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970601)79:11<2162::AID-CNCR14>3.0.CO;2-U     Document Type: Article

References (30)

1. Boring CC, Squires TS, Tong T. Cancer statistics 1991. CA Cancer J Clin 1991;41:19-36.
2. Lu-yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in USA. Lancet 1994;343:251-4.
3. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non-palpable (Stage A-1c) prostate cancer. JAMA 1994;271:368-74.
4. Goldfinger SE, Editor in Chief. Prostate cancer: watchful waiting. Harvard Health Lett 1994;19:1-3.
5. Chodak DW, Thisted RE, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
6. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988;48:1238-3.
7. Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Faucett C, et al. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 1991;4:466-74.
8. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M. Her-2/ neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53:4960-70.
9. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Stelur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993; 11:1936-42.
10. Descotes F, Pavy J-J, Adessi GL. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 1993;13:119-24.
11. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
12. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
13. Marks JR, Humphrey PA, Wu K, Erry D, Bandarenko N, Kerns B-JM, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-41.
14. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER-2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14(3):737-44.
15. Peitras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9(7):1829-38.
16. Visakorpi T, Kallioniemi O-P, Koivula T, Harvey J, Isola J. Expression of epidermal growth factor receptor and c-erbB-2 (HER-2/neu) oncoprotein in prostatic carcinomas. Mod Pathol 1992;5:643-8.
17. Ibrahim GK, MacDonald JA, Kerns BJ, Ibrahim SN, Humphrey PA, Robertson CN. Differential immunoreactivity of HER-2/neu oncoprotein in prostatic tissues. Surg Oncol 1992;1:151-5.
18. Ross JS, Nazeer T, Church K, Amato C, Figge H, Rifkin MD, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma and metastasis. Cancer 1993;72:3020-8.
19. Sandavisan R, Morgan R, Jennings S, Austenfeld M, van Delvhuiven P, Stephens R, et al. Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 1993;150:126-31.
20. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul J. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993;150:1427-33.
21. Melon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, et al. P53, cerbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992;147:496-9.
22. Latil A, Baron JC, Cussenot O, Fournier G, Bocon-Gibod L, LeDuc A, et al. Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 1994;59:637-8.
23. Fournier G, Latil A, Amet Y, Abalain JH, Polant A, Mangin P, et al. Gene amplifications in advanced stage human prostate cancer. Urol Res 1995;22:343-7.
24. Ware JL, Maygarden SJ, Koontz WW, Strom SC. Immunohistochemical detection of CerbB2 protein in human benign and neoplastic prostate. Hum Pathol 1991;22:254-8.
25. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2 antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
26. Gu K, Mes-Masson AM, Gauthier J, Saad F. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Lett 1996;99:185-9.
27. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, et al. Quantitative nuclear morphometry, Markovian texture descriptors and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem Suppl 1994;19:249-58.
28. Chiu KY, Loke SL, Ho FCS. Immunohistochemical demonstration of CerbB2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation. J Clin Pathol 1994;47:117-21.
29. Kay EW, Walsh CJB, Cassidy M, Currin B, Leader M. CerbB2 immunostaining: problems with interpretation. J Clin Pathol 1994;47:816-22.
30. Zhau HY, Zhou J, Symmans WF, Chen BQ, Chang SM, Sikes RA, et al. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996;28:73-83.